This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the role of Orexin Receptor Agonists in treating narcolepsy.

Ticker(s): ALKS, TAK, CNTA

Who's the expert?

Institution: Harvard

  • Associate Professor of Neurology
  • Pediatric neurologist and sleep medicine physician specializing in central nervous system (CNS) disorders of hypersomnolence and sleep problems in children with neurological/neurodevelopmental disorders
  • Has authored text on narcolepsy in key clinical resources including the textbook Principles and Practices of Sleep Medicine and UptoDate, Inc

Interview Goal
This call will focus on the current standard of care for narcolepsy along with an analysis of multiple orexin receptor 2 (OX2R) being developed for the treatment of narcolepsy. The therapies of interest include TAK-861 (oveporexton), ALKS 2680, and ORX142.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.